Cargando…

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

OBJECTIVES: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). METHODS: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hesselstrand, Roger, Distler, Jörg H. W., Riemekasten, Gabriela, Wuttge, Dirk M., Törngren, Marie, Nyhlén, Helén C., Andersson, Fredrik, Eriksson, Helena, Sparre, Birgitta, Tuvesson, Helén, Distler, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325221/ https://www.ncbi.nlm.nih.gov/pubmed/34330322 http://dx.doi.org/10.1186/s13075-021-02573-0

Ejemplares similares

Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse
por: Tahvili, Sahar, et al.
Publicado: (2018)

A broad look into the future of systemic sclerosis
por: Riemekasten, Gabriela, et al.
Publicado: (2022)

Airway resistance and reactance are affected in systemic sclerosis
por: Aronsson, David, et al.
Publicado: (2015)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Type III, IV, and VI Collagens Turnover in Systemic Sclerosis – a Longitudinal Study
por: Juhl, Pernille, et al.
Publicado: (2020)

Pulmonary blood density quantified by CMR is reduced in newly diagnosed systemic sclerosis, consistent with pulmonary arteriolar proliferation
por: Kanski, Mikael, et al.
Publicado: (2011)

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study
por: Andréasson, Kristofer, et al.
Publicado: (2020)

Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals – a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes
por: Kanski, Mikael, et al.
Publicado: (2013)

Myocardial perfusion using cardiac magnetic resonance: Evidence of decreased global myocardial perfusion in patients with systemic sclerosis with possible gender differences
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study
por: Gyllenhammar, Tom, et al.
Publicado: (2018)

Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
por: Beyer, Christian, et al.
Publicado: (2009)

The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis
por: Fransén Pettersson, Nina, et al.
Publicado: (2018)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

The scientific basis for novel treatments of systemic sclerosis
por: Beyer, Christian, et al.
Publicado: (2009)

Vascular alterations upon activation of TGFβ signaling in fibroblasts - implications for systemic sclerosis
por: Horn, Angelika, et al.
Publicado: (2010)

Inhibitory Effect of Paquinimod on a Murine Model of Neutrophilic Asthma Induced by Ovalbumin with Complete Freund's Adjuvant
por: Lee, Jong-Uk, et al.
Publicado: (2021)

Editorial: Precision Medicine in Chronic Inflammation
por: Distler, Oliver, et al.
Publicado: (2021)

Tie2 as a novel key factor of microangiopathy in systemic sclerosis
por: Moritz, Falk, et al.
Publicado: (2017)

Corrigendum to “Inhibitory Effect of Paquinimod on a Murine Model of Neutrophilic Asthma Induced by Ovalbumin with Complete Freund's Adjuvant”
por: Lee, Jong-Uk, et al.
Publicado: (2021)

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
por: Jaeger, Veronika K., et al.
Publicado: (2016)

Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
por: Hamberg, Viggo, et al.
Publicado: (2023)

Molecular targets for therapy in systemic sclerosis
por: Iwamoto, Naoki, et al.
Publicado: (2012)

The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes
por: Radstake, Timothy R. D. J., et al.
Publicado: (2009)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

How does endothelial cell injury start? The role of endothelin in systemic sclerosis
por: Abraham, David, et al.
Publicado: (2007)

DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod
por: Talley, Sarah, et al.
Publicado: (2021)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis
por: Koch, Alisa E, et al.
Publicado: (2007)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Systemic Sclerosis 2011
por: Chung, Lorinda, et al.
Publicado: (2011)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
por: Spierings, Julia, et al.
Publicado: (2021)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Vascular Disease in Systemic Sclerosis
por: Chung, Lorinda, et al.
Publicado: (2010)

Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
por: Rieker-Schwienbacher, Juliane, et al.
Publicado: (2013)

Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets
por: Moinzadeh, Pia, et al.
Publicado: (2020)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Calcineurin inhibitors in systemic sclerosis – a systematic literature review
por: Hofmann, Nina N., et al.
Publicado: (2022)

Patients with systemic sclerosis show phenotypic and functional defects in neutrophils
por: Impellizzieri, Daniela, et al.
Publicado: (2021)

Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries
por: Stamm, Tanja A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_psarf0imn92mtrm6psbqss5v8p